The Latest Breaking News from AstraZeneca

A prominent Thai politician faces up to 20 years in prison following his indictment on Monday for insulting the king and violating a cyber law, after he criticised the government for over-reliance on a royal-owned firm to supply COVID-19 vaccines.

Manufacturing of the vaccine has slowed and further research is stalled

AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 4.32% on an annualized basis producing an average annual return of 18.01%. Currently, AstraZeneca has a market capitalization of $214.04 billion.

AstraZeneca Plc (NASDAQ:AZN) shared new and prolonged follow-up results from the Phase 3 CHAMPION-MG trial open-label extension (OLE) of Ultomiris (ravulizumab-cwvz) in generalized myasthenia gravis (gMG). Ultomiris demonstrated long-term efficacy, with improvements in activities of daily living, muscle strength, and quality of life sustained through 60 weeks. Ultomiris was also well tolerated throughout…

During the second half of 2021, Scott was the top recipient of drug campaign cash in Congress

Sen. Tim Scott, a rising star in the Republican Party with broad popularity in his home state of South Carolina, is getting showered with drug industry money before facing voters this fall.

The U.S. Food and Drug Administration granted emergency use authorization to AstraZeneca’s COVID-19 antibody drug Evusheld on Dec. 8, 2021. Infectious disease physician Patrick Jackson of the University of Virginia explains how it works, who’s eligible and why some patients are having difficulties accessing it.

Mark Hartigan has been given £511,000 bonus for 2021 – a humbler CEO would have let the dust settle

NEW YORK: After racing to build capacity and meet once seemingly insatiable orders for Covid-19 shots, the global vaccine industry is facing waning demand as many late-to-market producers fight over a slowing market.